We are live on ! Find out more
CLBT icon

Cellebrite

148 hedge funds and large institutions have $990M invested in Cellebrite in 2024 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 60 increasing their positions, 54 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

120% more call options, than puts

Call options by funds: $832K | Put options by funds: $379K

53% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 15

18% more capital invested

Capital invested by funds: $836M → $990M (+$153M)

11% more repeat investments, than reductions

Existing positions increased: 60 | Existing positions reduced: 54

5% more funds holding

Funds holding: 141148 (+7)

3.39% more ownership

Funds ownership: 36.96%40.35% (+3.4%)

0% more funds holding in top 10

Funds holding in top 10: 66 (0)

Holders
148
Holders Change
+7
Holders Change %
+4.96%
% of All Funds
2.13%
Holding in Top 10
6
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.09%
New
23
Increased
60
Reduced
54
Closed
15
Calls
$832K
Puts
$379K
Net Calls
+$453K
Net Calls Change
-$5.69M

CLBT Hedge Fund Activity: Q2 2024 in Review

148 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Cellebrite (CLBT) for Q2 2024, worth a combined $990M — up 18% from $836M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new CLBT positions and 15 closed out — a net gain of 8 holders — while 60 added to existing stakes and 54 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $32M. The largest seller was Arrowstreet Capital, cutting an estimated $9.83M.

  • 148 institutional investors held Cellebrite (CLBT) as of Q2 2024, up from 141 in Q1 2024.
  • Funds reported $990M of Cellebrite stock for Q2 2024, up 18% quarter-over-quarter.
  • 23 funds opened new Cellebrite positions in Q2 2024 and 15 closed out, a net change of +8 holders.
  • The largest Cellebrite buyer in Q2 2024 was Morgan Stanley, an estimated $32M added.
  • The largest Cellebrite seller in Q2 2024 was Arrowstreet Capital, an estimated $9.83M sold.

Based on aggregated 13F filings for Q2 2024.